$1.360
-0.039 (-2.86%)收盤時
IBIO 資訊
IBIO 事件
iBio Appoints Molly Carr as Chief Medical Officer
iBio (IBIO) announced the appointment of Molly Carr as chief medical officer as the company advances its clinical-stage cardiometabolic pipeline. Most recently, she served as clinical head and associate VP of Lilly's (LLY) insulin and glucagon franchise.
iBio Announces New Preclinical Data for IBIO-610
iBio announced new preclinical data from its obese non-human primate, or NHP, study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate. Following a single dose of IBIO-610, active Activin E levels in the blood were reduced in all treated NHPs and remained suppressed through eight weeks. At both weeks 4 and 8, active Activin E levels were reduced to levels below the limits of the assay. Overall, active Activin E was reduced by 98% at week 4 and 97% at week 8 compared with baseline. These findings support IBIO-610's potential for best-in-class pathway inhibition and further support the potential for an infrequently dosed, long-acting antibody approach. The data also demonstrated IBIO-610's potential to promote fat-selective weight loss while preserving lean mass. In obese NHPs, when combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone, further supporting its potential as both a stand-alone therapy and a complementary approach to GLP-1-based treatments.
iBio Doses First Participant in IBIO-600 Clinical Trial
iBio announced the dosing of the first participant in its Phase 1 clinical trial of IBIO-600, the company's most advanced obesity and cardiometabolic asset and its first program to enter human clinical development. This milestone marks iBio's transition to a clinical-stage biotechnology company.
iBio Receives Clearance for IBIO-600 Clinical Trials, Advancing Pipeline
"This last quarter was marked by significant advancement across our full pipeline. Most importantly, we received the clearance to enter the clinic with IBIO-600, which we believe has best-in-class potential due to its ability to preserve lean mass and improve body composition in obesity," said Martin Brenner, CEO and chief scientific officer of iBio. "We also presented new data for IBIO-610 demonstrating targeted reduction of total and visceral fat in obese non-human primates and expanded our pipeline with our selective bispecific antibody designed to block Activin A, GDF8 and GDF11, potentially to treat PH-HFpEF, which represents a high unmet need. Together, these milestones continue to demonstrate the significant potential of our platform and our commitment to developing differentiated therapies to meaningfully impact the lives of patients."
iBio Receives Clinical Trial Approval for IBIO-600
iBio announced IBIO-600 has received clinical trial notification acknowledgement from Australia's Therapeutic Goods Administration and ethics approval from a Human Research Ethics Committee, enabling the initiation of a first-in-human clinical trial of IBIO-600 in Australia. The Phase 1 study is a randomized, double-blind, placebo-controlled, single ascending dose trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IBIO-600 in overweight and obese adult participants. iBio expects to dose the first participant in the second quarter of 2026.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。